Anne-Bine S Skytte

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2426932/publications.pdf

Version: 2024-02-01

37 papers	2,623 citations	430874 18 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	6867 citing authors

#	Article	IF	Citations
1	The use of expanded carrier screening of gamete donors. Human Reproduction, 2021, 36, 1702-1710.	0.9	14
2	Attitudes of sperm donors towards offspring, identity release and extended genetic screening. Reproductive BioMedicine Online, 2021, 43, 700-707.	2.4	6
3	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
4	Impact of genetic counseling on the uptake of contralateral prophylactic mastectomy among younger women with breast cancer. Acta OncolÃ³gica, 2020, 59, 60-65.	1.8	9
5	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
6	AN IMPROVED METHOD FOR ZIKA VIRUS SCREENING IN A GAMETE BANK SETTING. Fertility and Sterility, 2020, 114, e277.	1.0	0
7	New Pathogenic Germline Variants in Very Early Onset and Familial Colorectal Cancer Patients. Frontiers in Genetics, 2020, 11, 566266.	2.3	16
8	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
9	Revised Danish guidelines for the cancer surveillance of patients with Cowden Syndrome. European Journal of Medical Genetics, 2020, 63, 103873.	1.3	19
10	Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model. Familial Cancer, 2019, 18, 381-388.	1.9	8
11	Estimating the effect size of the 15Q11.2 BP1â€“BP2 deletion and its contribution to neurodevelopmental symptoms: recommendations for practice. Journal of Medical Genetics, 2019, 56, 701-710.	3.2	43
12	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
13	Childhood pneumothorax in Birtâ€Hoggâ€DubÃ© syndrome: A cohort study and review of the literature. Molecular Genetics & Genomic Medicine, 2018, 6, 332-338.	1.2	15
14	Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes. American Journal of Human Genetics, 2018, 103, 3-18.	6.2	46
15	Familial idiopathic pulmonary fibrosis in a young female. Respiratory Medicine Case Reports, 2018, 24, 1-4.	0.4	4
16	Clinical characteristics and registry-validated extended pedigrees of germline TP53 mutation carriers in Denmark. PLoS ONE, 2018, 13, e0190050.	2.5	6
17	Birtâ€“Hoggâ€“DubÃ© syndrome: a case report and a review of the literature. European Clinical Respiratory Journal, 2017, 4, 1292378.	1.5	24
18	A case of penta X syndrome caused by nondisjunction in maternal meiosis 1 and 2. Clinical Case Reports (discontinued), 2017, 5, 1136-1140.	0.5	1

#	Article	IF	Citations
19	Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation. Journal of Human Genetics, 2017, 62, 151-157.	2.3	19
20	Genetically diagnosed Birtâ€“Hoggâ€“DubÃ© syndrome and familial cerebral cavernous malformations in the same individual: a case report. Familial Cancer, 2017, 16, 139-142.	1.9	2
21	Diagnosis and Treatment of Blau Syndrome/Early-onset Sarcoidosis, an Autoinflammatory Granulomatous Disease, in an Infant. Acta Dermato-Venereologica, 2017, 97, 126-127.	1.3	13
22	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	1.6	152
23	Identification of eight novel SDHB, SDHC, SDHD germline variants in Danish pheochromocytoma/paraganglioma patients. Hereditary Cancer in Clinical Practice, 2016, 14, 13.	1.5	13
24	Multilocus Inherited Neoplasia Alleles Syndrome. JAMA Oncology, 2016, 2, 373.	7.1	43
25	BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population. Familial Cancer, 2016, 15, 507-512.	1.9	9
26	No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families. Familial Cancer, 2016, 15, 523-528.	1.9	3
27	The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1. Journal of Clinical Immunology, 2016, 36, 73-84.	3.8	124
28	Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2. Acta OncolÃ³gica, 2016, 55, 38-44.	1.8	13
29	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
30	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. European Urology, 2014, 66, 489-499.	1.9	195
31	Dosage Changes of a Segment at 17p13.1 Lead to Intellectual Disability and Microcephaly as a Result of Complex Genetic Interaction of Multiple Genes. American Journal of Human Genetics, 2014, 95, 565-578.	6.2	40
32	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
33	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
34	<scp>UBE</scp> 2 <scp>QL</scp> 1 is Disrupted by a Constitutional Translocation Associated with Renal Tumor Predisposition and is a Novel Candidate Renal Tumor Suppressor Gene. Human Mutation, 2013, 34, 1650-1661.	2.5	18
35	Ovarian cancer susceptibility alleles and risk of ovarian cancer inBRCA1andBRCA2mutation carriers. Human Mutation, 2012, 33, 690-702.	2.5	34
36	Identification of BRCA1-deficient ovarian cancers. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 593-599.	2.8	15

#	Article	IF	Citations
37	Populationâ€based survey of cancer risks in chromosome 3 translocation carriers. Genes Chromosomes and Cancer, 2010, 49, 52-58.	2.8	27